Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Around the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

Few BRCA-1 Carriers Take Recommended Precautions

February 1, 1998
Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 7 No 2
Volume 7
Issue 2

SAN ANTONIO-Genetic testing for breast cancer susceptibility appears to confer no adverse psychological effects on mutation carriers or individuals who refuse to be tested, Caryn Lerman, PhD, reported at a general session of the San Antonio Breast Cancer Symposium.

SAN ANTONIO—Genetic testing for breast cancer susceptibility appears to confer no adverse psychological effects on mutation carriers or individuals who refuse to be tested, Caryn Lerman, PhD, reported at a general session of the San Antonio Breast Cancer Symposium.

The data also showed that regardless of testing or mutation status, few participants in the study, all from high-risk families, have taken advantage of prevention options or followed surveillance recommendations.

“Our findings suggest that additional efforts may need to be directed toward interventions to enhance medical decision making and that there may be less need for adjuvant psychosocial interventions than initially anticipated,” said Dr. Lerman, a cancer genetics specialist at the Lombardi Cancer Center and Georgetown University.

The findings come from an analysis of data on 282 men and women from 40 families with a documented history of hereditary breast/ovarian cancer. All of the individuals in the study have attended education sessions to learn more about the potential risks of hereditary breast/ovarian cancer, the availability and utility of genetic testing and counseling, the preventive options (prophylactic mas-tectomy and oophorectomy), and recommendations for follow-up screening.

“Clinicians and researchers have engaged in a debate as to whether, at present, in the absence of proven prevention strategies, the psychological risks associated with genetic testing outweigh the potential medical benefits,” Dr. Lerman said. “So far, the debate has occurred virtually in an empirical vacuum.”

In this study, funded by the Department of Defense, Dr. Lerman and her colleagues are evaluating factors that may predict an individual’s decision to undergo testing for BRCA-1 gene status and to receive the test results.

The evaluation includes an assessment of the psychological impact of testing, which will be repeated 1, 6, 12, and 24 months after individuals make their initial decision about testing.

In her San Antonio presentation, Dr. Lerman reported 1- and 6-month data on depression, as evaluated by responses to a 20-item questionnaire. Each item is rated on a scale of 0 to 3, resulting in a possible cumulative score of 0 to 60, with higher scores reflecting increased levels of depression.

At each follow-up, patients are asked about preventive options and adherence to screening recommendations. For female mutation carriers who do not opt for prophylactic mastectomy or oophor-ectomy, annual mammography is recommended, as are twice-yearly trans-vaginal ultrasound scans and use of CA-125 testing.

Of the 282 individuals in the study, 192 chose to be tested, and 89 of those were found to be BRCA-1 mutation carriers. The remaining 90 people decided not to undergo genetic testing.

Minimal Depression

As a group, the participants demonstrated minimal depression, with a mean cumulative score of 9 on the depression scale, Dr. Lerman said. Within groups, no significant changes in depression scores occurred during the first 6 months of follow-up in mutation carriers, noncarriers, and those who declined testing. Noncarriers had a nonsignificant decline in depression scores.

“We did not find any overall evidence for adverse effects associated with genetic testing,” Dr. Lerman said. “In fact, there may be some psychological benefits, at least for those individuals identified as noncarriers.”

The only significant difference resulted from a comparison of 6-month depression scores for noncarriers and decliners. That difference emerged when the investigators controlled for patient age, baseline depression, and other factors shown to influence the change in depression score.

“In decliners, we observed an increase in the depression score from an average of about 7 to about 12, which means they were reporting about five additional symptoms of depression over baseline or that they were endorsing two symptoms at a similar level,” she said. “Compared to noncarriers, this was significant.”

Few unaffected (no personal history of breast cancer) mutation carriers expressed interest in prophylactic surgery. Two of 33 patients surveyed expressed a desire to have prophylactic mastectomy at baseline, but 6 months later, neither had acted on the decision.

With respect to prophylactic oophor-ectomy, 9 of 27 individuals said they intended to have the surgery, and 3 had undergone the surgery at 6 months.

At 6-month follow-up, fewer than half the mutation-carriers had undergone mammographic evaluation. About 10% had sought transvaginal ultrasound or CA-125 testing, but no patient had undergone both types of screening within the first 6 months, as recommended.

Articles in this issue

Tobacco Companies Reach Settlement With Texas for $15.3 Billion
Archives to Collect Info on Radiation Exposure Worldwide
Few BRCA-1 Carriers Take Recommended Precautions
Lifelong Weight Control a Key to Breast Ca Prevention
Eight-Year Prostate Brachytherapy Update Shows Good Results
Patient Brochure on Breast Cancer Tumor Markers
Gay Men’s Health Crisis Calls for HIV Reporting in New York
Single-Agent Taxanes in Advanced Breast Cancer: A Commentary
ODAC Declines to Vote on DepoCyt FDA Recommendation
Photofrin Approved for Early-Stage Lung Cancer
Breast Cancer Diagnosed After Childbirth May Be More Severe
NCCN Forum: Who Pays for Clinical Trials?
AHCPR Smoking Interventions Are Cost Effective
Senator Urges Consensus on Tobacco Law
Thomas Jefferson Opens New Familial Colorectal Cancer Registry
Recent Videos
Oncologists are still working on management strategies for neuropathy; a common adverse effect related to chemotherapeutics for ovarian cancer.
Genetic testing information can be used to risk-stratify ovarian cancer survivors for breast cancer, particularly those with BRCA1 or BRCA2 mutations.
Genetic testing for ovarian cancer may help inform treatment decisions for patients with advanced disease, particularly regarding PARP inhibitor use.
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Patients with node-negative disease who are older and have comorbidities may not be suitable to receive CDK4/6 inhibitors.
An observed carryover effect with CDK4/6 inhibitors may reduce the risk of recurrence years after a patient stops treatment.
Related Content
Advertisement

Underscoring Genetic Testing’s Role in Enhancing Ovarian Cancer Care

Underscoring Genetic Testing’s Role in Enhancing Ovarian Cancer Care

Roman Fabbricatore
September 27th 2025
Article

Artificial intelligence can be used to automate genetic counseling processes and streamline a patient’s communication with relatives regarding genetic risk.


Upfront risk stratification for additional cardiovascular testing may help mitigate cardiovascular toxicities in breast cancer treatment.

Cardiovascular Considerations in Breast Cancer Treatment and Survivorship

Joseph S. Wallins, MD, MPH
September 8th 2025
Podcast

Up-front risk stratification for additional cardiovascular testing may help mitigate cardiovascular toxicities in breast cancer treatment.


Though overall survival (OS) was at approximately 16% maturity at data cutoff, a favorable trend for the T-DXd regimen has been observed.

The FDA Grants Priority Review to T-DXd/Pertuzumab in 1L Metastatic Breast Cancer

Tim Cortese
September 24th 2025
Article

Results from the phase 3 DESTINY-Breast09 trial will support the FDA’s decision on whether to approve T-DXd plus pertuzumab in frontline metastatic breast cancer.


Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.

Advancements and Evolving Strategies in Breast Cancer Treatment at IBC East

Heather McArthur, MD, MPH;Erika P. Hamilton, MD;Hope S. Rugo, MD;Paolo Tarantino, MD, PhD
July 21st 2025
Podcast

Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.


3 Things You Should Know About TROP2 as a Therapeutic Target in Triple-Negative Breast Cancer

3 Things You Should Know About TROP2 as a Therapeutic Target in Triple-Negative Breast Cancer

ONCOLOGY Staff
September 23rd 2025
Article

Read an expert-led article on the latest advancements in TROP2-targeted antibody-drug conjugates for treating triple-negative breast cancer and improving patient outcomes.


Data from the phase 3 evERA trial show a trend towards improved overall survival with giredestrant plus everolimus in this breast cancer population.

Giredestrant Combo Significantly Boosts PFS in ER+ Advanced Breast Cancer

Russ Conroy
September 22nd 2025
Article

Data from the phase 3 evERA trial show a trend toward improved overall survival with giredestrant plus everolimus in this breast cancer population.

Related Content
Advertisement

Underscoring Genetic Testing’s Role in Enhancing Ovarian Cancer Care

Underscoring Genetic Testing’s Role in Enhancing Ovarian Cancer Care

Roman Fabbricatore
September 27th 2025
Article

Artificial intelligence can be used to automate genetic counseling processes and streamline a patient’s communication with relatives regarding genetic risk.


Upfront risk stratification for additional cardiovascular testing may help mitigate cardiovascular toxicities in breast cancer treatment.

Cardiovascular Considerations in Breast Cancer Treatment and Survivorship

Joseph S. Wallins, MD, MPH
September 8th 2025
Podcast

Up-front risk stratification for additional cardiovascular testing may help mitigate cardiovascular toxicities in breast cancer treatment.


Though overall survival (OS) was at approximately 16% maturity at data cutoff, a favorable trend for the T-DXd regimen has been observed.

The FDA Grants Priority Review to T-DXd/Pertuzumab in 1L Metastatic Breast Cancer

Tim Cortese
September 24th 2025
Article

Results from the phase 3 DESTINY-Breast09 trial will support the FDA’s decision on whether to approve T-DXd plus pertuzumab in frontline metastatic breast cancer.


Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.

Advancements and Evolving Strategies in Breast Cancer Treatment at IBC East

Heather McArthur, MD, MPH;Erika P. Hamilton, MD;Hope S. Rugo, MD;Paolo Tarantino, MD, PhD
July 21st 2025
Podcast

Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.


3 Things You Should Know About TROP2 as a Therapeutic Target in Triple-Negative Breast Cancer

3 Things You Should Know About TROP2 as a Therapeutic Target in Triple-Negative Breast Cancer

ONCOLOGY Staff
September 23rd 2025
Article

Read an expert-led article on the latest advancements in TROP2-targeted antibody-drug conjugates for treating triple-negative breast cancer and improving patient outcomes.


Data from the phase 3 evERA trial show a trend towards improved overall survival with giredestrant plus everolimus in this breast cancer population.

Giredestrant Combo Significantly Boosts PFS in ER+ Advanced Breast Cancer

Russ Conroy
September 22nd 2025
Article

Data from the phase 3 evERA trial show a trend toward improved overall survival with giredestrant plus everolimus in this breast cancer population.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.